

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Sophia Akhiyat, MD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Christen Benke, DO	Planning Committee	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Tonya Chaffee, MD	Speaker	<ul style="list-style-type: none"> Hologic Organon 	<ul style="list-style-type: none"> Consultant Nexplanon certification trainer
Walter Coyle, MD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Emily Engel, MD	Speaker	<ul style="list-style-type: none"> AbbVie, Biohaven 	<ul style="list-style-type: none"> Speakers Bureau
Kelly Fan, MD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Ken Fujioka, MD	Speaker	<ul style="list-style-type: none"> Amgen, Boehringer Ingelheim, Currax, Lilly, Novo Nordisk, Phenomix Sciences, Rhythm Pharmaceuticals, Shionogi, Takeda Pharmaceuticals, VectivBio (Ironwood Pharmaceuticals) Lilly, Novo Nordisk, Takeda Pharmaceuticals 	<ul style="list-style-type: none"> Consultant Speakers Bureau
Tresa Lombardi, MD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Michael Preziosi, MD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Evan Richardson, PharmD	Planning Committee	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Jenna Roberts, PA-C	Planning Committee	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
John Rogers, MD	Speaker	<ul style="list-style-type: none"> Boston Scientific Corporation, Medtronic, Inc. 	<ul style="list-style-type: none"> Consultant, Speaker
Michael Van Buskirk, MD	Course Director, Moderator, Peer Reviewer	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Lauren Vincent, MD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Katharine Woessner, MD	Speaker	<ul style="list-style-type: none"> AstraZeneca Amgen, AstraZeneca, GlaxoSmithKline, Regeneron 	<ul style="list-style-type: none"> Consultant Speaker
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.